Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

Item

http://www.wikidata.org/entity/Q36762858

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

@ast

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

@en

type

Item

label

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

@ast

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

@en

prefLabel

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

@ast

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

@en

P1476

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

@en

P2093

Fumihiko Hirai

http://www.w3.org/2001/XMLSchema#string

Gouji Toyokawa

http://www.w3.org/2001/XMLSchema#string

Hiroshi Yamamoto

http://www.w3.org/2001/XMLSchema#string

Jun Hashimoto

http://www.w3.org/2001/XMLSchema#string

Justin Lindemann

http://www.w3.org/2001/XMLSchema#string

Kan Yonemori

http://www.w3.org/2001/XMLSchema#string

Kenji Tamura

http://www.w3.org/2001/XMLSchema#string

Lan Chen

http://www.w3.org/2001/XMLSchema#string

Makoto Kodaira

http://www.w3.org/2001/XMLSchema#string

Shuji Arita

http://www.w3.org/2001/XMLSchema#string

P2860

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.

The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update.

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Activation of AKT kinases in cancer: implications for therapeutic targeting.

Targeting the PI3K-AKT-mTOR signaling network in cancer.

Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

P2888

s00280-016-2987-9

P304

787-795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-2987-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

296469258

http://www.w3.org/2001/XMLSchema#string

P698

26931343

http://www.w3.org/2001/XMLSchema#string

P932

4819940

http://www.w3.org/2001/XMLSchema#string